| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 06.11. | Listing Of Units Rights And Paid Subscription Units Of Immunovia AB | 320 | GlobeNewswire | With effect from November 09, 2026, the units rights of Immunovia AB will be traded on the list for Equity rights. Trading will continue up until and including November 18, 2026.
... ► Artikel lesen | |
| 04.11. | Immunovia AB: Immunovia publishes prospectus in connection with rights issue | 147 | GlobeNewswire (Europe) | NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA... ► Artikel lesen | |
| 03.11. | Immunovia AB (publ) receives observation status | 236 | GlobeNewswire | On November 2, 2026, Immunovia AB (publ) (the "Company") disclosed its interim report for the third quarter of 2026 with information on the Company's financial situation.
According to item 4.1.1... ► Artikel lesen | |
| 03.11. | XFRA CAPITAL ADJUSTMENT INFORMATION - 03.11.2026 | 338 | Xetra Newsboard | Das Instrument IR0 IT0005528069 REWAY GROUP S.P.A. EQUITY wird cum Kapitalmassnahme gehandelt am 03.11.2026 und ex Kapitalmassnahme am 04.11.2026 The instrument IR0 IT0005528069 REWAY GROUP S.P.A. EQUITY... ► Artikel lesen | |
| IMMUNOVIA Aktie jetzt für 0€ handeln | |||||
| 02.11. | Earnings Call: Immunovia übertrifft Umsatzerwartungen in Q3 2026 - Aktie legt vorbörslich zu | 3 | Investing.com Deutsch | ||
| 02.11. | Immunovia-Aktie springt zweistellig an: Kommerzialisierung nimmt deutlich an Fahrt auf | 7 | Investing.com Deutsch | ||
| 02.11. | Immunovia AB Q3 Loss Decreases | 5 | RTTNews | ||
| 02.11. | Immunovia AB: Immunovia Publishes Interim Report for July-September 2026 | 185 | GlobeNewswire (Europe) | Highlights July-September 2026Net sales and operating results for Q3 2026 in line with expectations: Net sales for the period amounted to 843 KSEK (101), comprising revenue from PancreaSure test sales... ► Artikel lesen | |
| 29.10. | Immunovia AB: Bulletin from the extraordinary general meeting in Immunovia AB (publ) | 212 | GlobeNewswire (Europe) | Today, on 29 October 2026, an extraordinary general meeting was held in Immunovia AB (publ). A summary of the adopted resolutions follows below.
Resolution on amendment of the Articles of AssociationThe... ► Artikel lesen | |
| 28.10. | Immunovia AB: Immunovia announces final terms of rights issue | 183 | GlobeNewswire (Europe) | NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA... ► Artikel lesen | |
| 28.09. | Immunovia AB: Immunovia carries out a rights issue of units of approximately SEK 63 million | 248 | GlobeNewswire (Europe) | NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA... ► Artikel lesen | |
| 06.08. | Immunovia AB Q2 Loss Narrows | 1 | RTTNews | ||
| 06.08. | Immunovia AB: Immunovia Publishes Interim Report for April-June 2026 | 289 | GlobeNewswire (Europe) | Highlights April-June 2026Net sales and operating results for Q2 2026 in line with expectations: Net sales of 381 KSEK (90) for the period were comprised primarily of revenue from PancreaSure tests... ► Artikel lesen | |
| 13.05. | Immunovia AB: Bulletin From The Annual General Meeting On 13 May 2026 In Immunovia AB (publ) | 352 | GlobeNewswire (Europe) | Today, on 13 May 2026, the annual general meeting of Immunovia AB (publ) was held. A summary of the adopted resolutions follows below.
Resolution on the adoption of the accounts and allocation of resultThe... ► Artikel lesen | |
| 07.05. | Immunovia AB: Immunovia Publishes Interim Report for January-March 2026 | 458 | GlobeNewswire (Europe) | Highlights January-March 2026Net sales and operating results for Q1 2026 in line with expectations: Net sales of 374 KSEK (139) for the period included royalties and revenues from PancreaSure tests.... ► Artikel lesen | |
| 24.02. | Immunovia AB: Immunovia Publishes Full Year Report for 2025 | 769 | GlobeNewswire (Europe) | Highlights October-December 2025Net sales and operating results for Q4 2025 in line with expectations: Net sales of 354 KSEK for the period (455) largely reflected royalty revenue. Operating loss was... ► Artikel lesen | |
| 20.01. | Immunovia AB: The Board of Directors of Immunovia withdraws proposal for reverse share split and cancels Extraordinary General Meeting | 273 | GlobeNewswire (Europe) | Following discussions with major shareholders, the Board of Directors of Immunovia AB (publ) ("Immunovia" or the "Company") has decided to withdraw the proposal for a reverse share split and the Extraordinary... ► Artikel lesen | |
| 19.01. | Immunovia AB: Immunovia receives state regulatory approval for PancreaSure in California and initiates commercial rollout | 397 | GlobeNewswire (Europe) | Immunovia AB (IMMNOV: Nasdaq Stockholm), a pancreatic cancer diagnostics company, today announced that it has received regulatory approval for its PancreaSure test in California, US, enabling commercial... ► Artikel lesen | |
| 17.12.25 | Immunovia AB: The Board of Directors of Immunovia proposes a reverse share split | 953 | GlobeNewswire (Europe) | The Board of Directors of Immunovia AB (publ) ("Immunovia" or the "Company") proposes that an Extraordinary General Meeting on 22 January 2026 resolves to carry out a reverse share split, in the ratio... ► Artikel lesen | |
| 26.11.25 | Immunovia AB: Immunovia receives final Medicare payment rate for PancreaSure test | 524 | GlobeNewswire (Europe) | LUND, Sweden - Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced that the Centers for Medicare & Medicaid Services (CMS) has finalized a national payment... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| HIMS & HERS HEALTH | 15,570 | +0,19 % | Hims-&-Hers-Aktie -26%: 49% Wachstum - und trotzdem ein Crash! | Die Hims-&-Hers-Aktie erlebt einen heftigen Ausverkauf. Nach enttäuschenden Quartalszahlen verlor das Papier am Dienstag weitere -16,6% auf 19,13 US$ und damit innerhalb von zwei Handelstagen rund -26%.... ► Artikel lesen | |
| BECTON DICKINSON | 196,95 | +0,05 % | Becton, Dickinson and Company Stock Outlook: Is Wall Street Bullish or Bearish? | ||
| RYMAN HEALTHCARE | 0,823 | 0,00 % | RYMAN HEALTHCARE LIMITED: Ryman appoints two new directors | ||
| WELLBEING DIGITAL SCIENCES | 0,007 | -100,00 % | KGK Science Receives Growth Investment Led By Maxim Partners | ||
| NIAGEN BIOSCIENCE | 1,860 | +5,08 % | Niagen Bioscience setzt auf Expansion: Wachstumsstrategie im NAD-Markt trotz Margendruck | ||
| SIENNA SENIOR LIVING | 13,000 | 0,00 % | Sienna Senior Living Inc: Sienna Senior Living to list additional shares | ||
| MICROPORT SCIENTIFIC | 0,688 | -100,00 % | XFRA MSK: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILMICRP.SCIEN.REGS... ► Artikel lesen | |
| EXTENDICARE | 18,800 | -1,57 % | Extendicare Inc.: Extendicare Announces 2026 Third Quarter Results | Markham, Ontario--(Newsfile Corp. - November 5, 2026) - Extendicare Inc. (TSX: EXE) ("Extendicare" or the "Company") today reported results for the three and nine months ended September 30, 2026.Third... ► Artikel lesen | |
| VERADIGM | 7,350 | -100,00 % | Veradigm Inc. - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB | ||
| NATIONAL HEALTHCARE CORPORATION | 185,00 | -0,54 % | Dividendenbekanntmachungen (30.10.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACRES COMMERCIAL REALTY CORP PFD D US00489Q3002 0,4921 USD EUR ACROW LIMITED AU0000006124 0,0142 AUD EUR ADENTRA INC CA00686A1084 0... ► Artikel lesen | |
| UNIPHAR | 4,250 | -0,47 % | Dividendenbekanntmachungen (09.10.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AGNC INVESTMENT CORP US00123Q1040 0,12 USD EUR ALERUS FINANCIAL CORPORATION US01446U1034 0,22 USD EUR ALTRIA GROUP INC US02209S1033 1... ► Artikel lesen | |
| HANGZHOU TIGERMED CONSULTING | 3,800 | -4,52 % | TIGERMED (03347): NEXT DAY DISCLOSURE RETURN | ||
| AESTHETIC MEDICAL INTERNATIONAL | 0,009 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -3- | The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameKYG200801002 CBAK... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 38,560 | -2,90 % | Fresenius verkauft weitere FMC-Aktien und reduziert Beteiligung auf 20 Prozent | Fresenius setzt den Rückzug aus seiner Beteiligung am Dialysespezialisten Fresenius Medical Care (FMC) fort. Der Gesundheitskonzern will rund 13,4 Millionen FMC-Aktien verkaufen, was etwa 5 Prozent... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 43,840 | +1,25 % | Aktie zieht an!: Siemens liefert und legt nach, die Strategie überzeugt wirft Fragen auf | © Foto: Joko - JokoSiemens meldet Rekordzahlen und hebt die Mittelfristziele an. Anleger bleiben trotzdem skeptisch, denn die neue Konzernstrategie gilt vielen noch als zu unscharf Enthaltene Werte:... ► Artikel lesen |